Lifeway Foods, Inc. (LWAY) Director Ludmila Smolyansky Sells 7,550 Shares

Share on StockTwits

Lifeway Foods, Inc. (NASDAQ:LWAY) Director Ludmila Smolyansky sold 7,550 shares of the company’s stock in a transaction on Wednesday, June 13th. The stock was sold at an average price of $6.24, for a total transaction of $47,112.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Ludmila Smolyansky also recently made the following trade(s):

  • On Monday, June 11th, Ludmila Smolyansky sold 4,510 shares of Lifeway Foods stock. The stock was sold at an average price of $6.22, for a total transaction of $28,052.20.
  • On Tuesday, May 22nd, Ludmila Smolyansky sold 23,500 shares of Lifeway Foods stock. The stock was sold at an average price of $5.75, for a total transaction of $135,125.00.

Shares of LWAY traded down $0.19 during mid-day trading on Thursday, reaching $6.07. The stock had a trading volume of 21,169 shares, compared to its average volume of 19,386. The company has a current ratio of 2.32, a quick ratio of 1.57 and a debt-to-equity ratio of 0.13. Lifeway Foods, Inc. has a 52-week low of $4.76 and a 52-week high of $10.75. The firm has a market capitalization of $95.58 million, a P/E ratio of -303.50 and a beta of 0.51.

Lifeway Foods (NASDAQ:LWAY) last announced its quarterly earnings data on Tuesday, May 15th. The company reported $0.00 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.07) by $0.07. Lifeway Foods had a negative net margin of 0.35% and a negative return on equity of 0.84%. The firm had revenue of $28.74 million during the quarter, compared to analyst estimates of $26.50 million. equities research analysts predict that Lifeway Foods, Inc. will post 0.01 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Lifeway Foods stock. Stone Ridge Asset Management LLC acquired a new stake in Lifeway Foods, Inc. (NASDAQ:LWAY) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,159 shares of the company’s stock, valued at approximately $161,000. Stone Ridge Asset Management LLC owned 0.13% of Lifeway Foods at the end of the most recent quarter. Institutional investors and hedge funds own 16.21% of the company’s stock.

A number of equities research analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Lifeway Foods from a “hold” rating to a “strong sell” rating in a report on Wednesday, April 25th. ValuEngine lowered shares of Lifeway Foods from a “hold” rating to a “sell” rating in a report on Saturday, June 2nd. Finally, TheStreet lowered shares of Lifeway Foods from a “c-” rating to a “d” rating in a report on Friday, May 4th.

Lifeway Foods Company Profile

Lifeway Foods, Inc produces and markets probiotic-based products in the United States and internationally. Its primary product is drinkable kefir, a cultured dairy product in various organic and non-organic sizes, flavors, and types, including low fat, non-fat, whole milk, protein, BioKefir, and kefir with oats.

Insider Buying and Selling by Quarter for Lifeway Foods (NASDAQ:LWAY)

Receive News & Ratings for Lifeway Foods Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifeway Foods and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Axiom Price Reaches $0.0078 on Exchanges
Axiom Price Reaches $0.0078 on Exchanges
Starta Hits 24-Hour Trading Volume of $0.00
Starta Hits 24-Hour Trading Volume of $0.00
Zacks: Brokerages Expect MTS Systems Co.  Will Announce Earnings of $0.63 Per Share
Zacks: Brokerages Expect MTS Systems Co. Will Announce Earnings of $0.63 Per Share
Obalon Therapeutics  Getting Somewhat Positive Media Coverage, Study Shows
Obalon Therapeutics Getting Somewhat Positive Media Coverage, Study Shows
Novus Therapeutics  Receives News Impact Score of 0.16
Novus Therapeutics Receives News Impact Score of 0.16
$4.68 Earnings Per Share Expected for Regeneron Pharmaceuticals Inc  This Quarter
$4.68 Earnings Per Share Expected for Regeneron Pharmaceuticals Inc This Quarter


Leave a Reply

 
© 2006-2018 Zolmax.